Mva-bn-cv301 (** Investigational drug (no commercial brand names available as it remains in clinical trials) **)
Other Medications
Description
MVA-BN-CV301 is an investigational vaccine being studied in clinical trials for specific types of metastatic colorectal cancer (CRC). It is being tested in combination with other treatments, including chemotherapy (like mFOLFOX6) and immunotherapy (Nivolumab), before and after surgery. The goal is to see if this vaccine can help the body's immune system fight the cancer. The trial focuses on patients with liver-limited metastatic CRC who are candidates for surgery after initial treatment. The vaccine is given in a series of doses, both before surgery (neoadjuvant) and after surgery (adjuvant), along with boosters. Researchers are collecting blood and tumor samples to understand how the vaccine affects the immune response and the tumor microenvironment.
Mechanism of Action
MVA-BN-CV301 is a type of cancer vaccine. Vaccines work by teaching the immune system to recognize and attack cancer cells. This specific vaccine uses components from the cancer cells (CV301) to stimulate this immune response. It is given in combination with other therapies like chemotherapy and immunotherapy (Nivolumab) to potentially enhance the immune system's ability to target and eliminate cancer cells, particularly in the context of liver metastases before and after surgical removal.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.